Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
2.
J Clin Pathol ; 62(11): 1021-5, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19861561

RESUMO

BACKGROUND: Venous invasion (VI) is an important prognostic factor in colorectal cancer; it is positively associated with visceral metastases and may affect the decision to treat with adjuvant therapy. AIMS: To evaluate whether an elastic tissue (Movat) stain facilitates identification of VI, the number of Movat-stained blocks needed to detect VI, and whether VI identified with a Movat stain is prognostically equivalent to VI identified on H&E-stained slides. METHODS: H&E-stained sections from colorectal carcinomas from the year 2000 (n = 92) were examined for VI and compared to Movat-stained slides. Clinical charts were reviewed to compare rates of metastases in VI-positive versus VI-negative patients. RESULTS: With the Movat stain, VI was identified in 44% of cases previously categorised as negative (p<0.001) on review of H&E slides alone. One Movat-stained section was often sufficient to identify VI, with a statistically significant benefit to performing multiple stains if necessary. In H&E sections, two clues helped identify VI: the "unaccompanied artery" sign, where large arteries were seen without an accompanying vein; and the "protruding tongue" sign, where smooth tongues of tumour extended into pericolic/rectal fat. Metastases were present in 61% of cases positive for VI compared to 35% in VI-negative cases (p = 0.03). 45% of cases positive for intramural VI only developed metastases (p = 0.39), while 65% of cases positive for extramural VI only developed metastases (p = 0.03). CONCLUSIONS: Pathologists should look for morphological clues of VI in H&E stained sections; when VI is not apparent, an elastic tissue stain on all tumour blocks significantly improves identification of VI. Morphological clues include the "unaccompanied artery" and "protruding tongue" signs.


Assuntos
Adenocarcinoma/patologia , Vasos Sanguíneos/patologia , Neoplasias Colorretais/patologia , Adenocarcinoma/secundário , Adenocarcinoma/terapia , Quimioterapia Adjuvante , Neoplasias Colorretais/terapia , Tecido Elástico/patologia , Humanos , Invasividade Neoplásica , Estadiamento de Neoplasias , Prognóstico , Radioterapia Adjuvante , Estudos Retrospectivos , Manejo de Espécimes/métodos , Coloração e Rotulagem/métodos , Resultado do Tratamento
3.
Biochem Biophys Res Commun ; 257(1): 129-38, 1999 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-10092522

RESUMO

Hematopoietic cell kinase (Hck) is a member of the Src-family of protein tyrosine kinases. We have found that upon enzymatic activation of Hck by the heavy metal mercuric chloride, there was a rapid increase in the levels of tyrosine phosphorylation of several proteins including the proto-oncogene p120(Cbl). Fibroblasts that are transformed with an activated allele of Hck exhibit constitutive Cbl phosphorylation. Upon Fcgamma receptor activation, a more physiologically relevant extracellular signal, Cbl is tyrosine phosphorylated and the Src-family selective inhibitor, PP1, can prevent this phosphorylation on Cbl. Hck phosphorylates Cbl in vitro and the interaction between Cbl and Hck is direct, requiring Hck's unique, SH3 and SH2 domains for optimal binding. Using a novel estrogen-regulated chimera of Hck we have shown a hormone-dependent association between Hck and Cbl in murine fibroblasts. This work suggests that Cbl serves as a key mediator of Hck induced signalling in hematopoietic cells.


Assuntos
Proteínas Tirosina Quinases/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Ubiquitina-Proteína Ligases , Células 3T3 , Alelos , Animais , Linhagem Celular Transformada , Ativação Enzimática/efeitos dos fármacos , Estradiol/farmacologia , Humanos , Cloreto de Mercúrio/farmacologia , Camundongos , Fosforilação/efeitos dos fármacos , Fosfotirosina/metabolismo , Testes de Precipitina , Ligação Proteica , Proteínas Tirosina Quinases/genética , Proto-Oncogene Mas , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas c-cbl , Proteínas Proto-Oncogênicas c-hck , Pirazóis/farmacologia , Pirimidinas/farmacologia , Agregação de Receptores , Receptores de IgG/antagonistas & inibidores , Receptores de IgG/metabolismo , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes de Fusão/metabolismo , Transfecção , Células Tumorais Cultivadas , Domínios de Homologia de src/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA